---
title: "Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Guidelines questions"
description: "Guidelines questions on Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Is Verzenio recommended by NCCN guidelines for early breast cancer? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Guidelines questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)

Questions that apply to every indication of Verzenio are on [Verzenio (abemaciclib), all indications](https://www.evicenter.com/medical-information/verzenio).

## Guidelines

<a id="verzenio-nccn-guidelines"></a>

### Is Verzenio recommended by NCCN guidelines for early breast cancer?

> “National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>) recommends 2 years of adjuvant abemaciclib (Verzenio) in combination with ET for HR+, HER2—, node-positive, high-risk<sup>*</sup> EBC (NCCN Category 1<sup>†</sup>, Preferred).<sup>1</sup>”

Source: [VERZENIO: NCCN Guidelines, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer/nccn-guidelines#:~:text=National%20Comprehensive%20Cancer,EBC%20%28NCCN%20Category)

> “<sup>†</sup>Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.<sup>1</sup>”

Source: [VERZENIO: NCCN Guidelines, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer/nccn-guidelines#:~:text=1%3A%20Based%20upon%20high%2Dlevel%20evidence,Panel%29%20that%20the%20intervention%20is)

> “<sup>*</sup>High-risk was defined as HR+, HER2– EBC with either ≥4 positive nodes, OR 1-3 positive nodes and tumors that were ≥5 cm, histological Grade 3—or both.<sup>1, 3</sup>”

Source: [VERZENIO: NCCN Guidelines, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer/nccn-guidelines#:~:text=was%20defined%20as%20HR%2B%2C%20HER2%E2%80%93,%E2%89%A55%20cm%2C%20histological%20Grade%203%E2%80%94or)

> “Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Breast Cancer V5.2026. ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed Jul 13, 2026. To view the most recent and complete version of the guidelines, go online to nccn.org.”

Source: [VERZENIO: NCCN Guidelines, captured 2026-11-14](https://verzenio.lilly.com/hcp/efficacy-early-breast-cancer/nccn-guidelines#:~:text=Referenced%20with%20permission%20from%20the,guidelines%2C%20go%20online%20to%20nccn.org.)

## Related pages
- [Medical information: Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/dosing-and-administration)
